20 September 2023: Clinical Research
Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy
Radu Valeriu Toma 12ABCG , Zgura Anca 1E , Oana Gabriela Trifănescu 12A , Laurenţia Nicoleta Galeş 12D* , Antonia Ruxandra Folea 2CDEF , Loredana Stanca 3B , Liviu Bîlteanu 234ABCDEF* , Rodica M. Anghel 1ADOI: 10.12659/MSM.941754
Med Sci Monit 2023; 29:e941754
Table 5 Association of the presence of changes in electrocardiographic findings with clinical factors during monitoring.
| Variable | OR | 95% CI | p-value | RR | 95% CI |
|---|---|---|---|---|---|
| Height ≥1.64 m | 7.50 | (1.50, 37.394) | 0.014 | 1.76 | (1.50, 2.06) |
| New T-wave modification | 5.20 | (3.04, 210.93) | 0.003 | 11.43 | (1.66, 78.88) |
| [Pre-existing] modifications of T-wave in posterior leads | 5.56 | (1.08, 83.07) | 0.043 | 4.60 | (0.72, 29.22) |
| Thyroid disease | 13.33 | (2.16, 81.94) | 0.005 | 6.28 | (3.84, 10.29) |
| Age ≥58 yrs | 9.45 | (1.07, 83.06) | 0.043 | 7.24 | (2.99, 17.50) |
| Presence of chronic infections, inflammatory or thyroid-related diseases | 8.20 | (1.54, 43.47) | 0.013 | 5.00 | (2.98, 8.37) |
| New ST junction (J) or ST segment depression | 6.00 | (2.49, 86.03) | 0.003 | 3.32 | (0.99, 11.1) |
| New T-wave modification | 5.19 | (2.98, 57.00) | 0.001 | 2.03 | (1.24, 3.33) |
| New ST junction (J) or ST segment depression | 6.00 | (5.01, 280.90) | 2.55 | (1.04, 6.26) | |
| New T-wave modification | 5.19 | (1.60, 132.38) | 0.017 | 1.39 | (1.04, 1.86) |